Trade deal will 'force' FDA, EMA to standardize regs; Lundbeck touts Abilify data; Mylan CFO aims for TASE;

@FiercePharma: India's Kumar eyes a one-stop shop on pharmaceuticals. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> A transatlantic trade deal will force the FDA and European Medicines Agency to standardize their regulations on manufacturing and trials, an Eli Lilly ($LLY) executive recently said. Report

> Lundbeck said a new data analysis showed its long-lasting antipsychotic injection Abilify Maintena beat head-to-head rival Invega Sustenna at improving functioning and quality of life in young people with schizophrenia. Release

> Mylan ($MYL) CFO John Sheehan said the company wants to join the Tel Aviv Stock Exchange (TASE) if it succeeds in buying Perrigo ($PRGO); it would be among the largest publicly traded companies on Israel's exchange. Report

> Pozen, which just swapped CEOs and engineered a tax-inversion buyout, brought in three new top managers to lead the combined company, which will be called Aralez Pharmaceuticals. Report

> Morris Plains, NJ, cracked down on environmental remediation plans for a former Pfizer ($PFE) site in the borough. Report

> NeuroRx said a small study of a ketamine drug combination reduced symptoms of depression and suicidal tendencies in patients with bipolar disorder. Report

Medical Device News

@FierceMedDev: Broad Institute bags $20M for drug-resistant TB research. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic strikes back with FDA approval of its third-gen TAVR. Report | Follow @VarunSaxena2

@EmilyWFierce: Cue the screaming fans: Nick Jonas signs up with Dexcom diabetes effort. FiercePharmaMarketing story | Follow @EmilyWFierce

> The Esophageal Cooling Device gets FDA's rare de novo clearance for innovative devices. Article

> Philips readies launch of smart device-based ultrasound device, app. Story

Biotech News

@FierceBiotech: Chris Viehbacher explains: "If I had $2 billion to invest ..." More | Follow @FierceBiotech

@JohnCFierce: Cool new video on Cellectis's allogeneic approach to T cells. It looks so easy... Watch | Follow @JohnCFierce

@DamianFierce: Analyst on $ADHD call: "congrats on these interesting observations." Their drug was outperformed by placebo, dude. | Follow @DamianFierce

> Langer startup SQZ hopes to spark a tech revolution in immuno-oncology. Article

> Hackers are targeting biotech with eyes on insider trading. Report

Biotech Research News

> Team spotlights new evidence that Parkinson's starts in the gut. Story

> Allied-Bristol JV picks up rights to Harvard's work on traditional Chinese remedy. News

> Experimental prostate cancer combo shows promise in case studies. Report

> Purdue group finds Achilles' heel for MERS. Item

> Investigators say they've designed a new-and-improved antibiotic. Article

Diagnostics News

> Qiagen to partner with Japan's Hitachi on molecular testing. More

> Broad Institute bags $20M for drug-resistant TB research. Item

> Advanced Cell Diagnostics receives $22M to develop its RNA biomarker tech. News

> Siemens snags FDA approval for HIV combo test. Story

> Biodesix brings Series E to $38M for blood-based lung cancer Dx. Article

Pharma Marketing News

> Another AZ exec jumps ship for CEO job at smaller drugmaker. Item

> Novartis playing catch-up in cancer? Not us, says top oncology exec. Story

> Has Lundbeck failed to sharpen Brintellix's marketing edge with payers? More

> Call it Allergan, call it a 'growth pharma.' Just don't call it Big Pharma. Article

> Got game? Pharma's moving into gamification but needs to drop the bribes. Report

And Finally... An 18-year-old Thiel Fellow postponed college for a year to develop and sell GlucoIQ, his platform for doctors to use in managing diabetes patients' medications and outcomes. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.